A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) |
| |
Authors: | S Cascinu L Frontini R Labianca V Catalano S Barni C Graiff G Picone F Farinati S Zonato M A Pessi C Curti and G Catalano |
| |
Institution: | (1) Medical Oncology, Azienda Ospedaliera di Parma, Parma, Italy;(2) Medical Oncology, Azienda Opedaliera S. Paolo, Milano, Italy;(3) Medical Oncology, Azienda Ospedaliera di Bergamo, Bergamo, Italy;(4) Medical Oncology, Azienda Ospedaliera di Pesaro, Pesaro, Italy;(5) Medical Oncology, Azienda Ospedaliera di Treviglio (BG), Treviglio, Italy;(6) Medical Oncology, Azienda Ospedaliera di Bolzano, Bolzano, Italy;(7) Medical Oncology, University of Messina, Messina, Italy;(8) Medical Oncology, University of Padova, Padova, Italy;(9) Coordinating data Center GISCAD, Milano, Italy |
| |
Abstract: | Background:Laboratory evidences suggest the possibility that aninfusion rate of 10 mg/m2/min may be more effective than thestandard 30-min infusion of Gemcitabine (GEM).
Patients and methods:Thirty-four patients with histologicallyverified locally unresectable and/or metastatic pancreatic carcinoma receivedGEM at the dose of 1,500 mg/m2 with an infusion rate of 10mg/m2/min, associated to 5-fluorouracil (5-FU) at the dose of 600mg/m2. Both drugs were administered weekly for two consecutiveweeks out of every three weeks.
Results:One complete and five partial responses have beenobserved for an overall response rate of 17% (95% CI:3%–27%). The time to progression was 3.7 months with amedian survival of 5.7 months. A clinical benefit was obtained in 5 of 29patients (17%). Grade 3–4 WHO toxicities included neutropenia(35%) and thrombocytopenia (10%).
Conclusion:It is unlikely that a fixed dose rate infusion of GEM,at least with this dose, can improve palliation in comparison with thestandard 30-min infusion schedule in advanced pancreatic cancer. |
| |
Keywords: | gemcitabine infusion schedule pancreatic cancer |
本文献已被 Oxford SpringerLink 等数据库收录! |
|